<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707200</url>
  </required_header>
  <id_info>
    <org_study_id>07-0548-AE</org_study_id>
    <secondary_id>HS 356</secondary_id>
    <secondary_id>ISBT 777531237</secondary_id>
    <nct_id>NCT00707200</nct_id>
  </id_info>
  <brief_title>The Cytoadherence in Pediatric Malaria (CPM) Study</brief_title>
  <acronym>CPM</acronym>
  <official_title>Clinical Outcomes in Pediatric Plasmodium Falciparum Malaria According to Host Cytoadherence Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the importance of key blood group molecules in the
      clinical outcome of Plasmodium falciparum malaria infection in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every year, nearly 2 million children die from infection with Plasmodium falciparum malaria.
      When red blood cells (RBC) become infected with malaria, a sticky parasite-derived knob
      protein, termed PfEMP-1, erupts on the RBC surfaces. PfEMP-1 attaches to several blood group
      molecules, including those found on other RBC, on blood vessels, and on the cells that
      normally help to stop bleeding (platelets). The cellular sticking results in a dangerous
      interruption in blood flow to vital organs, causing brain injury (cerebral malaria), systemic
      shock (lactic acidosis), and death. Depending on an individual's inherited blood groups of
      relevance, adhesion may be extensive or limited. In the laboratory, PfEMP-1 adheres to RBCs
      via the A or B (but not the O) antigens of the ABO blood group system, and to platelets and
      blood vessels via platelet glycoprotein IV (CD36) and ICAM-1. Consistent with the expected
      evolutionary advantage of being deficient in these binding targets, blood type O and
      low-expression of CD36 are found more frequently among Africans. The &quot;Cytoadherence in
      Pediatric Malaria&quot; (CPM) project is determining the distribution of adhesive blood group
      molecules in a cohort of 2000 Ugandan children according to the extent of malaria severity
      and death, and thus their ultimate clinical and evolutionary significance in malarial
      survival. This knowledge may serve as the grounds for developing targeted
      cytoadhesion-interruption therapies in our fight against malaria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Combined severe morbidity &amp; mortality</measure>
    <time_frame>Discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory indices of potential cytoadhesion (lactate, cell counts)</measure>
    <time_frame>Presentation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Freshly frozen citrated plasma aliquots, frozen spun red cell pellets, and whole blood blots
      onto nucleic acid storage cards (Whatman FTA).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children, age 6 months to 12 years, with symptomatic malaria and (asexual) Plasmodium
        falciparum parasitemia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Plasmodium falciparum malaria infection

        Exclusion Criteria:

          -  HIV or significant malnutrition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolette Nabukeera-Barungi, MBChB, MMEd</last_name>
    <role>Study Director</role>
    <affiliation>Mulago Hospital/Makerere University (lead local investigator)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mulago Hospital Acute Care Unit &amp; Makerere University Department of Paediatrics &amp; Child Health</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.cd36malaria.org</url>
    <description>CPM Study's official website</description>
  </link>
  <reference>
    <citation>Cserti CM, Dzik WH. The ABO blood group system and Plasmodium falciparum malaria. Blood. 2007 Oct 1;110(7):2250-8. Epub 2007 May 14. Review.</citation>
    <PMID>17502454</PMID>
  </reference>
  <results_reference>
    <citation>Cserti-Gazdewich CM, Dzik WH, Dorn ME, Quagliaroli RO, Xu S, Ssewanyana I, Nayyar R, Preffer FI. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom. 2009 Mar;76(2):127-34. doi: 10.1002/cyto.b.20443.</citation>
    <PMID>18671254</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <last_update_submitted>January 22, 2010</last_update_submitted>
  <last_update_submitted_qc>January 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christine Cserti-Gazdewich</name_title>
    <organization>University Health Network</organization>
  </responsible_party>
  <keyword>severe malarial anemia (SMA)</keyword>
  <keyword>cerebral malarial (CM)</keyword>
  <keyword>lactic acidosis</keyword>
  <keyword>hyperparasitemia</keyword>
  <keyword>respiratory distress</keyword>
  <keyword>hypoxia</keyword>
  <keyword>death</keyword>
  <keyword>transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

